Navigation Links
CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
Date:8/20/2009

WHAT: A series of Featured Clinical Trials will be presented at Transcatheter Cardiovascular Therapeutics (TCT), in addition to late-breaking clinical trials. These featured clinical trials represent groundbreaking research and will yield data and insight that will further the field of interventional cardiology.

WHEN: The TCT Featured Clinical Trials will be presented on September 24, 2009 from 2:00 6:00 pm.

Session I. Drug-Eluting Stents

  • ZEST: Final Angiographic and IVUS Results From a Large-Scale Randomized Trial of Zotarolimus-Eluting, Sirolimus-Eluting and Paclitaxel-Eluting Stents
    Cheol Whan Lee, MD
  • CEREA-DES: A Prospective Randomized Trial of Corticosteroids in Patients Undergoing Stent Implantation
    Flavio L Ribichini, MD
  • STATINS PRE-PCI: A Prospective Randomized Trial of Statins Prior to Stent Implantation in Patients with Stable Angina
    Josef Veselka, MD, PhD
  • NEVO RES-ELUTION I QOL: Formal Quality-of-Life Assessment from a Prospective Randomized Trial of a Novel Sirolimus-Eluting Stent and a Paclitaxel-Eluting Stent
    John A. Spertus, MD
  • CILOTAX: A Prospective, Randomized, Controlled Trial of a Stent Eluting Cilostazol and Paclitaxel
    Cheol Whan Lee, MD
  • BIOFREEDOM: A Prospective Randomized Trial of a Polymer-Free Biolimus A9-Eluting Stent
    Eberhard Grube, MD

Session II. ACS Therapies and Novel Imaging Approaches

  • MISTRAL: A Prospective Randomized Trial of Ambulance-Initiated vs. Cath Lab-Initiated Intravenous Abciximab in Patients with STEMI
    Patrick Ohlmann, MD, PhD
  • COCKTAIL: A Prospective Randomized Trial of Intracoronary Abciximab Infusion in Patients with Thrombotic Lesions Assessed by OCT Francesco Prati, MD
  • NO REFLOW: A Prospective Randomized Trial of Intracoronary vs. Guide Catheter Infusion of Nitrates vs. Calcium Channel Blockers in Patients with No Reflow After Primary PCI in STEMI
    Junbo Ge, MD
  • OCTAMI: A Prospective Randomized Trial of Zotarolimus-Eluting and Bare-Metal Stents in STEMI Assessed by OCT
    Giulio Guagliumi, MD

Session III. End-Stage, Structural Heart and Endovascular Intervention

  • The Canadian Transcatheter Aortic Valve Implantation Program: Acute and Late Follow-up from a Multicenter Consecutive Series of Patients with Inoperable or High-Surgical Risk Aortic Stenosis
    Josep Rodes-Cabau, MD
  • CROSS-CLI: A Prospective Multicenter Registry of Ultrasound-Facilitated Recanalization of Peripheral Chronic Total Occlusions
    David E. Allie, MD
  • ARMOUR: A Prospective, Nonrandomized Study of the Mo.Ma Proximal Cerebral Protection Device in High Surgical Risk Subjects Undergoing Carotid Artery Stenting
    Gary M. Ansel, MD
  • PROVASA: A Prospective, Randomized, Placebo-Controlled Trial of Intra-Arterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells in Patients with Peripheral Arterial Occlusive Disease
    Dirk H. Walter, MD
  • ACT34-CMI: One-Year Results from a Prospective, Randomized, Placebo-Controlled Phase II Trial of CD34+ Cells in Patients with Refractory Angina
    Douglas W. Losordo, MD

WHERE: The Moscone Center San Francisco, CA


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ESCO Announces Major Contract Award for Its Thermoforming Business
2. CSC Announces Agreement to Provide Billing Service to Colorado West Dermatology
3. Florida Spine Surgeon Alfred Bonati, M.D. Announces Results of National Poll Showing America's Doctors Oppose a Government-Run Health Care Plan
4. AMDL Inc. Announces Second Quarter 2009 Financial Results
5. Chindex International, Inc. Announces New CDC Contract
6. Anthem Blue Cross and Blue Shield in Maine Announces Decision to Cover H1N1 Vaccine Administration
7. Expresso Fitness(R) Announces $6M Series D Funding
8. Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes
9. Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration
10. DURECT Announces License of ADHD Drug Candidate in Selected Asian and South Pacific Countries to Orient Pharma
11. American Council on Exercise (ACE) Announces Top Ten Tips to Avoid the Freshman 15
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction Treatment ... for professionals in the addiction treatment industry entitled: Special Investigations Unit (SIU) ... companies and state and federal governments are increasingly scrutinizing the addiction treatment industry ...
(Date:9/21/2017)... IL. (PRWEB) , ... September 21, 2017 , ... ... results released today of a new member survey conducted by the International ... restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures ...
(Date:9/21/2017)... ... ... Bill Howe Plumbing’s mission is to create an employee friendly company, provide ... over 37 years, they have operated with their mission at the foundation and have ... They were chosen as the Best San Diego plumber in 2016, named a Top ...
(Date:9/21/2017)... Renton, WA (PRWEB) , ... September 21, 2017 ... ... inspection technology using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 ... need of the life-sciences industry for ensuring label quality and improving patient safety. ...
(Date:9/21/2017)... ... 21, 2017 , ... Preora Diagnostics Inc. , a ... has received two prestigious recognitions that acknowledge the promise of its PWS Nanoctyology ... has been named a Top 100 Finalist for the 16th annual Chicago Innovation ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017 Caris Life Sciences, a leading ... promise of precision medicine, today announced results from ... its molecular profiling approach in guiding therapeutic strategies ... plus (CGP+) with Caris Molecular Intelligence ® ... molecular level, leading to more therapeutic options and ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: